2025
Diagnostic delay and misdiagnosis of symptoms reported by patients with multiple sclerosis participating in a research registry
Solomon A, Weinstein S, Shinohara R, Aoun S, Schmidt H, Solari A. Diagnostic delay and misdiagnosis of symptoms reported by patients with multiple sclerosis participating in a research registry. Multiple Sclerosis Journal - Experimental Translational And Clinical 2025, 11: 20552173251333390. PMID: 40292040, PMCID: PMC12033781, DOI: 10.1177/20552173251333390.Peer-Reviewed Original ResearchInitial symptom of MSDiagnostic delayMisdiagnosis of symptomsMultiple sclerosisSymptoms of MSAssociated with longer diagnostic delayLong diagnostic delayDiagnostic journey of patientsMS diagnostic criteriaJourney of patientsPatient RegistryDiagnostic criteriaPreventable causeMisdiagnosisDiagnostic journeyResearch RegistrySymptomsCohort dataPatientsCriteria revisionMedianRegistrySclerosisSurvey studyParticipantsGenerics, Biosimilars and Follow‐On Non‐Biologic Complex Drugs for Multiple Sclerosis: A Narrative Review of the Regulatory and Clinical Implications for European Neurologists
Berger T, Zeitlinger M, Popescu V, Magyari M, Airas L, Alkhawajah M, Pugliatti M, Zakaria M, Pozzilli C, Drulovic J, Van Wijmeersch B, Vermersch P, Oreja‐Guevara C. Generics, Biosimilars and Follow‐On Non‐Biologic Complex Drugs for Multiple Sclerosis: A Narrative Review of the Regulatory and Clinical Implications for European Neurologists. European Journal Of Neurology 2025, 32: e70140. PMID: 40231751, PMCID: PMC11998027, DOI: 10.1111/ene.70140.Peer-Reviewed Original ResearchConceptsDisease-modifying treatmentsNon-biological complex drugsImprove patient accessLiterature searchMultiple sclerosisMS careHealthcare systemPatient accessComplex drugsPubMed literature searchSocioeconomic burdenNarrative reviewTolerability profileGlatiramer acetateClinical efficacyClinical studiesEarly onsetEuropean neurologistsClinical implicationsProgressive natureDrugSclerosisOriginal drugPeopleCareTumefactive and longitudinally extensive myelitis: A rare presentation of multiple sclerosis?
Morehead A, Flanagan E, Solomon A. Tumefactive and longitudinally extensive myelitis: A rare presentation of multiple sclerosis? Neuroimmunology Reports 2025, 7: 100257. DOI: 10.1016/j.nerep.2025.100257.Peer-Reviewed Original ResearchSpinal cord demyelinationMultiple sclerosisCervical spinal cord lesionLongitudinally extensive myelitisPresentation of multiple sclerosisTumefactive demyelinating lesionsRare presentation of multiple sclerosisTherapeutic decision-makingRelapsing-remitting MSSpinal cord lesionsRare presentationClinical courseCord lesionsPrognostic challengesLongitudinal followDemyelinationLesionsSclerosisUnmet needsRelapseMyelitisPatientsFollow
2024
Trigeminal neuralgia within the disease course of MS: Diagnostic and therapeutic implications from a multicenter cohort
Laakso S, Oh J, Raufdeen F, Jones A, Reiskanen H, Feb K, Levit E, Solomon A. Trigeminal neuralgia within the disease course of MS: Diagnostic and therapeutic implications from a multicenter cohort. Multiple Sclerosis Journal 2024, 31: 607-611. PMID: 39727322, DOI: 10.1177/13524585241309257.Peer-Reviewed Original ResearchTrigeminal neuralgiaClinical relapseMultiple sclerosisActive diseaseEvidence of active diseaseDisease course of MSAssociated with multiple sclerosisCourse of MSDemyelination symptomsMulticenter cohortDisease courseTherapeutic decisionsTherapeutic implicationsMS diagnosisNeuralgiaRelapseDiseaseOnsetSclerosisMulticenter validation of automated detection of paramagnetic rim lesions on brain MRI in multiple sclerosis
Chen L, Ren Z, Clark K, Lou C, Liu F, Cao Q, Manning A, Martin M, Luskin E, O'Donnell C, Azevedo C, Calabresi P, Freeman L, Henry R, Longbrake E, Oh J, Papinutto N, Bilello M, Song J, Kaisey M, Sicotte N, Reich D, Solomon A, Ontaneda D, Sati P, Absinta M, Schindler M, Shinohara R, Cooperative T. Multicenter validation of automated detection of paramagnetic rim lesions on brain MRI in multiple sclerosis. Journal Of Neuroimaging 2024, 34: 750-757. PMID: 39410780, DOI: 10.1111/jon.13242.Peer-Reviewed Original ResearchParamagnetic rim lesionsArea under the curveRim lesionsMultiple sclerosisPrognosis of MSBiomarkers of chronic inflammationWhite matter lesionsMulticenter settingMulticenter studyMulticenter validationChronic inflammationBrain MRIClinical trialsIdentified lesionsMulticenterMS diagnosisLesionsParamagnetic rimAutomated segmentation methodMRIMRI biomarkersMulticenter datasetDiagnosisSclerosisTeam of trained ratersDifferential Diagnosis of Suspected Multiple Sclerosis in Pediatric and Late-Onset Populations
Hua L, Solomon A, Tenembaum S, Scalfari A, Rovira À, Rostasy K, Newsome S, Marrie R, Magyari M, Kantarci O, Hemmer B, Hemingway C, Harnegie M, Graves J, Cohen J, Bove R, Banwell B, Corboy J, Waubant E. Differential Diagnosis of Suspected Multiple Sclerosis in Pediatric and Late-Onset Populations. JAMA Neurology 2024, 81: 1210-1222. PMID: 39283621, DOI: 10.1001/jamaneurol.2024.3062.Peer-Reviewed Original ResearchDifferential diagnosisMultiple sclerosisAdult-onset MSClinical presentation of MSPresentation of MSNon-MS diagnosisClinical presentationAdult MSSuspected MSNeuronal injuryLate-onsetConsensus guidanceDiagnostic approachApproximately 5%Age groupsDiagnosisRed flagsMS expertsAgeEarly adulthoodBiological differencesSclerosisOlder adultsYearsAdultsDiagnostic performance of central vein sign versus oligoclonal bands for multiple sclerosis
Toljan K, Daboul L, Raza P, Martin M, Cao Q, O’Donnell C, Rodrigues P, Derbyshire J, Azevedo C, Bar-Or A, Caverzasi E, Calabresi P, Cree B, Freeman L, Henry R, Longbrake E, Oh J, Papinutto N, Pelletier D, Samudralwar R, Schindler M, Sotirchos E, Sicotte N, Solomon A, Shinohara R, Reich D, Sati P, Ontaneda D. Diagnostic performance of central vein sign versus oligoclonal bands for multiple sclerosis. Multiple Sclerosis Journal 2024, 30: 1268-1277. PMID: 39234802, PMCID: PMC11421977, DOI: 10.1177/13524585241271988.Peer-Reviewed Original ResearchConceptsCentral vein signPositive predictive valueOligoclonal bandsDiagnostic performanceMS diagnosisCerebrospinal fluidMultiple sclerosisPredictive valueNegative predictive valueCerebrospinal fluid testingRadiological suspicionDiagnostic accuracyImaging biomarkersDiagnosisDiagnostic biomarkersMonthsSclerosisBiomarkersPilot studyBaselineSelection 3Gastrointestinal disease in systemic sclerosis: the neglected organ system?
McMahan Z, Pandolfino J, Perlman H, Del Galdo F, Hinchcliff M. Gastrointestinal disease in systemic sclerosis: the neglected organ system? Current Opinion In Rheumatology 2024, 36: 374-378. PMID: 39193877, PMCID: PMC11588520, DOI: 10.1097/bor.0000000000001052.Peer-Reviewed Original ResearchSystemic sclerosisClinical trial endpointsInflammatory bowel diseaseTrial endpointsAssessment of disease activityRisk stratification methodsGastrointestinal (GIDisease activityRisk stratificationEffective therapyImmune responseBowel diseaseDisease pathogenesisTherapeutic interventionsGastrointestinal diseasesOrgan systemsDiseaseMultidisciplinary teamPathogenesisFunctional studiesGut microbiomeEndpointSclerosisMultiple sclerosis presenting with paroxysmal symptoms: Patients at the limitations of current diagnostic criteria
Heward K, Roy-Hewitson C, Solomon A. Multiple sclerosis presenting with paroxysmal symptoms: Patients at the limitations of current diagnostic criteria. Multiple Sclerosis Journal 2024, 30: 1566-1570. PMID: 38751226, DOI: 10.1177/13524585241253513.Peer-Reviewed Original ResearchMS diagnostic criteriaCentral nervous systemMultiple sclerosisDiagnostic criteriaClinically isolated syndromeRelapsing remitting MSParoxysmal neurological symptomsLhermitte's phenomenonOptic neuritisClinical attacksTrigeminal neuralgiaCase seriesNeurological symptomsTonic spasmsPatient presentationParoxysmal symptomsPatientsClinical guidanceNervous systemSyndromeOptimal careSymptomsAnecdotal reportsSclerosisNeuralgiaDominant, Mesial Temporal Lobe Epilepsy Due to Hippocampal Sclerosis
Herlopian A. Dominant, Mesial Temporal Lobe Epilepsy Due to Hippocampal Sclerosis. 2024, 735-745. DOI: 10.1007/978-3-031-23828-4_29.Peer-Reviewed Original ResearchHippocampal sclerosisOlfactory hallucinationsNeuropsychological outcomesTemporal lobe epilepsyMesial temporal lobe epilepsyDeep brain stimulationHippocampalVisual field defectsBrain stimulationLobe epilepsyThermoablative therapyField defectsSeizure outcomePost-ablationFebrile seizuresPharmacoresistant epilepsyPotential complicationsTherapyPatientsPalilaliaSclerosisHallucinationsHippocampusEpilepsySniffingImpact of the COVID-19 Pandemic on the Personal Networks and Neurological Outcomes of People With Multiple Sclerosis: Cross-Sectional and Longitudinal Case-Control Study
Riley C, Venkatesh S, Dhand A, Doshi N, Kavak K, Levit E, Perrone C, Weinstock-Guttman B, Longbrake E, De Jager P, Xia Z. Impact of the COVID-19 Pandemic on the Personal Networks and Neurological Outcomes of People With Multiple Sclerosis: Cross-Sectional and Longitudinal Case-Control Study. JMIR Public Health And Surveillance 2024, 10: e45429. PMID: 38319703, PMCID: PMC10879979, DOI: 10.2196/45429.Peer-Reviewed Original Research
2023
A multicenter pilot study evaluating simplified central vein assessment for the diagnosis of multiple sclerosis
Daboul L, O’Donnell C, Amin M, Rodrigues P, Derbyshire J, Azevedo C, Bar-Or A, Caverzasi E, Calabresi P, Cree B, Freeman L, Henry R, Longbrake E, Oh J, Papinutto N, Pelletier D, Prchkovska V, Raza P, Ramos M, Samudralwar R, Schindler M, Sotirchos E, Sicotte N, Solomon A, Shinohara R, Reich D, Sati P, Ontaneda D. A multicenter pilot study evaluating simplified central vein assessment for the diagnosis of multiple sclerosis. Multiple Sclerosis Journal 2023, 30: 25-34. PMID: 38088067, PMCID: PMC11037932, DOI: 10.1177/13524585231214360.Peer-Reviewed Original ResearchConceptsCentral vein signMultiple sclerosisPositive lesionsInter-rater agreementDiagnosis of MSMagnetic resonance imaging (MRI) biomarkersDiagnostic performancePossible multiple sclerosisInter-rater reliability assessmentGood diagnostic performanceMcDonald criteriaMulticenter studyVein assessmentMean ageVein signImaging biomarkersLesionsMRI sequencesCharacteristic curveSclerosisPatientsDiagnosisAssessmentParticipantsOptimal methodNeuroimaging to monitor worsening of multiple sclerosis: advances supported by the grant for multiple sclerosis innovation
Oh J, Airas L, Harrison D, Järvinen E, Livingston T, Lanker S, Malik R, Okuda D, Villoslada P, de Vries H. Neuroimaging to monitor worsening of multiple sclerosis: advances supported by the grant for multiple sclerosis innovation. Frontiers In Neurology 2023, 14: 1319869. PMID: 38107636, PMCID: PMC10722910, DOI: 10.3389/fneur.2023.1319869.Peer-Reviewed Original ResearchMultiple sclerosisClinical trialsMonitoring of MSMagnetic resonance imagingPositron emission tomographyDisability worseningKey unmetCentral pathologyEarly pathologyTreatment responseNew therapiesOcular imagingUnmet needResonance imagingEmission tomographyDisease pathologyNew therapeuticsPathologyNeuroimaging measuresTrialsLongitudinal studySclerosisClinicWorseningBiomarkersThe association between sleep disorders and resilience in persons with multiple sclerosis
Riegler K, Beauvais J, Neto L, Gromisch E. The association between sleep disorders and resilience in persons with multiple sclerosis. Multiple Sclerosis And Related Disorders 2023, 81: 105137. PMID: 37979407, DOI: 10.1016/j.msard.2023.105137.Peer-Reviewed Original ResearchA - 107 The Association between Sleep Disorders and Sleep Problems and Resilience in Persons with Multiple Sclerosis
Riegler K, Beauvais J, Neto L, Gromisch E. A - 107 The Association between Sleep Disorders and Sleep Problems and Resilience in Persons with Multiple Sclerosis. Archives Of Clinical Neuropsychology 2023, 38: 1279-1279. DOI: 10.1093/arclin/acad067.124.Peer-Reviewed Original ResearchConceptsSelf-reported sleep problemsSleep disordersSleep problemsMultiple sclerosisFormal diagnosisMedical record reviewSleep problem groupSleep disorder groupMS centersRecord reviewSignificant group differencesKruskal-Wallis testLarger studyDisorder groupDisordersGroup differencesSclerosisMethods ParticipantsDiagnosisSubscalesLow resilienceGroupResiliency ScaleProblem groupPersonsSecondary hypogammaglobulinemia in patients with multiple sclerosis on anti-CD20 therapy: Pathogenesis, risk of infection, and disease management
Alvarez E, Longbrake E, Rammohan K, Stankiewicz J, Hersh C. Secondary hypogammaglobulinemia in patients with multiple sclerosis on anti-CD20 therapy: Pathogenesis, risk of infection, and disease management. Multiple Sclerosis And Related Disorders 2023, 79: 105009. PMID: 37783194, DOI: 10.1016/j.msard.2023.105009.Peer-Reviewed Original ResearchConceptsRisk of infectionCD20 therapySecondary hypogammaglobulinemiaMultiple sclerosisAnti-CD20 therapySerum immunoglobulin levelsB cell levelsDisease managementImmunoglobulin levelsSerious infectionsTherapy clinical trialsPotential complicationsClinical trialsHypogammaglobulinemiaPatientsTreatment approachesTherapyInfectionSclerosisRiskPossible mechanismMedicationsBest practice approachComplicationsPathogenesisInterim guidelines for the assessment and treatment of pain in children with multiple sclerosis
Stratton C, Vassilopoulos A, Brenton J, Potter K, Vargas W, Rumm H, Bartels A, Bailey M, Odonkor C, Stoll S, Zempsky E, Yeh E, Makhani N. Interim guidelines for the assessment and treatment of pain in children with multiple sclerosis. Frontiers In Neuroscience 2023, 17: 1235945. PMID: 37781253, PMCID: PMC10536169, DOI: 10.3389/fnins.2023.1235945.Peer-Reviewed Original ResearchMultiple sclerosisManagement of painTreatment of painAdvanced practice nursingInterdisciplinary management approachInterim guidelinesTreatment guidelinesPain assessmentTreatment recommendationsPainPractice nursingMS researchClinical settingAnonymous completionSclerosisChildrenDelphi panelFuture studiesSurvey themesGuidelinesComprehensive assessmentAssessmentPanel chairsPhysiotherapyPhysiatryEarly Treatment for Multiple Sclerosis
Longbrake E, Kalincik T. Early Treatment for Multiple Sclerosis. Neurology 2023, 101: 549-550. PMID: 37468283, DOI: 10.1212/wnl.0000000000207754.Peer-Reviewed Original ResearchLocus for severity implicates CNS resilience in progression of multiple sclerosis
Harroud A, Stridh P, McCauley J, Saarela J, van den Bosch A, Engelenburg H, Beecham A, Alfredsson L, Alikhani K, Amezcua L, Andlauer T, Ban M, Barcellos L, Barizzone N, Berge T, Berthele A, Bittner S, Bos S, Briggs F, Caillier S, Calabresi P, Caputo D, Carmona-Burgos D, Cavalla P, Celius E, Cerono G, Chinea A, Chitnis T, Clarelli F, Comabella M, Comi G, Cotsapas C, Cree B, D’Alfonso S, Dardiotis E, De Jager P, Delgado S, Dubois B, Engel S, Esposito F, Fabis-Pedrini M, Filippi M, Fitzgerald K, Gasperi C, Gomez L, Gomez R, Hadjigeorgiou G, Hamann J, Held F, Henry R, Hillert J, Huang J, Huitinga I, Islam T, Isobe N, Jagodic M, Kermode A, Khalil M, Kilpatrick T, Konidari I, Kreft K, Lechner-Scott J, Leone M, Luessi F, Malhotra S, Manouchehrinia A, Manrique C, Martinelli-Boneschi F, Martinez A, Martinez-Maldonado V, Mascia E, Metz L, Midaglia L, Montalban X, Oksenberg J, Olsson T, Oturai A, Pääkkönen K, Parnell G, Patsopoulos N, Pericak-Vance M, Piehl F, Rubio J, Santaniello A, Santoro S, Schaefer C, Sellebjerg F, Shams H, Shchetynsky K, Silva C, Siokas V, Søndergaard H, Sorosina M, Taylor B, Vandebergh M, Vasileiou E, Vecchio D, Voortman M, Weiner H, Wever D, Yong V, Hafler D, Stewart G, Compston A, Zipp F, Harbo H, Hemmer B, Goris A, Smolders J, Hauser S, Kockum I, Sawcer S, Baranzini S, Harroud A, Jónsdóttir I, Blanco Y, Llufriu S, Madireddy L, Saiz A, Villoslada P, Stefánsson K. Locus for severity implicates CNS resilience in progression of multiple sclerosis. Nature 2023, 619: 323-331. PMID: 37380766, PMCID: PMC10602210, DOI: 10.1038/s41586-023-06250-x.Peer-Reviewed Original ResearchConceptsCentral nervous systemMultiple sclerosisAge-related MS severity scoreMS severity scoreProgression of multiple sclerosisCentral nervous system tissueChronic neurological disabilityPotential protective roleMedian timeAutoimmune diseasesHomozygous carriersIncreased brainstemSeverity scoreNeurological disabilityRisk allelesNervous systemGenome-wide association studiesCortical pathologyProtective roleBrain tissuePotential mechanismsSclerosisMendelian randomization analysisNeurocognitive reserveHeritability enrichmentEffects of nintedanib in patients with limited cutaneous systemic sclerosis and interstitial lung disease
Allanore Y, Khanna D, Smith V, Aringer M, Hoffmann-Vold A, Kuwana M, Merkel P, Stock C, Sambevski S, Denton C, Bergna M, Casado G, Walter P, Proudman S, Stevens W, Thakkar V, Troy L, Loeffler-Ragg J, Olschewski H, André B, Bondue B, Houssiau F, Smith V, Wuyts W, Azevedo V, Johnson S, Keystone E, Khalidi N, Levesque M, Rozas R, Orellana A, Huang C, Li J, Jiang Z, Liu Y, Xiao W, Xu J, Zeng X, Zheng Y, Zou H, Becvar R, Madsen H, Søndergaard K, Kilpeläinen M, Myllärniemi M, Agard C, Allanore Y, Bourdin A, Cottin V, Crestani B, Diot E, Dominique S, Hachulla E, Jouneau S, Leroy S, Nunes H, Prevot G, Wallaert B, Wemeau L, Aringer M, Bewig B, Blaas S, Distler J, Ehrchen J, Ewert R, Gläser S, Henes J, Hunzelmann N, König R, Kötter I, Kreuter M, Prasse A, Schulze-Koops H, Sfikakis P, Vlachoyiannopoulos P, Losonczy G, Behera D, Devi H, Kadel J, Kawedia M, Kumar D, Kumar U, Lokhande R, Malpani A, Mohan M, Nalawade A, Parakh U, Swarnakar R, Shobha V, Thangakunam B, Udwadia Z, Henry M, O'Reilly K, Balbir-Gurman A, Kramer M, Litinsky I, Rosner I, Cutolo M, Gabrielli A, Iaccarino L, Pesci A, Riccieri V, Vettori S, Funakubo Y, Inoue Y, Kawakami A, Kawaguchi Y, Kawamura T, Kondoh Y, Kuwana M, Nanki T, Nishioka Y, Nozawa K, Ogura T, Okamoto M, Sano H, Sasai R, Sasaki N, Suda T, Takahashi H, Takeuchi T, Makino S, Tanaka S, Yamasaki Y, Ch'ng S, Cheah C, Kan S, Mohamed R, Selman M, de Vries-Bouwstra J, van den Toorn L, Vonk M, Voskuyl A, Hoffmann-Vold A, Seip M, Dankiewicz-Fares I, Olesiejuk R, Pulka G, Szepietowski J, Alves J, Bernardes M, Cordeiro A, Costa J, Neves S, Salvador M, Sancho J, Delgado P, Barranco I, Martínez J, del Castillo A, Ovalles J, López-Longo F, Gallego A, Dapena M, Ivorra J, Ekwall A, Maurer B, Mihai C, Müller R, Mahakkanukrauh A, Nantiruj K, Siripaitoon B, Denton C, Herrick A, Madhok R, Maher T, West A, Antin-Ozerkis D, Bascom R, Criner G, Csuka M, D'Amico J, Ettinger N, Fischer A, Gerbino A, Gerke A, Glassberg M, Glazer C, Golden J, Gripaldo R, Gupta N, Hamblin M, Highland K, Ho L, Huggins J, Hummers L, Jones L, Kahaleh M, Khanna D, Kim H, Lancaster L, Luckhardt T, Mayes M, Ballesteros F, Mooney J, Mohabir P, Morrissey B, Moua T, Padilla M, Patel N, Perez R, Roman J, Rossman M, Russell T, Saketkoo L, Shah A, Shlobin O, Scholand M, Simms R, Spiera R, Steen V, Veeraraghavan S, Weigt S. Effects of nintedanib in patients with limited cutaneous systemic sclerosis and interstitial lung disease. Rheumatology 2023, 63: 639-647. PMID: 37294870, PMCID: PMC10907814, DOI: 10.1093/rheumatology/kead280.Peer-Reviewed Original ResearchLimited cutaneous systemic sclerosisInterstitial lung diseaseCutaneous systemic sclerosisSENSCIS trialEffect of nintedanibWeek 52Nintedanib groupPlacebo groupSystemic sclerosisLung diseaseProgressive fibrosing interstitial lung diseasesOpen-label nintedanibSSc-ILDLung functionPulmonary fibrosisNintedanibPatientsRate of declineFVCTrialsPlaceboSclerosisDiseaseGroupFibrosis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply